Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert John Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014
Cited by 262 works. doi:10.1016/s1470-2045(14)70030-0
Authors
- Robert John Motzer
- Camillo Porta
- Nicholas J. Vogelzang
- Cora Nanette Sternberg
- Cezary A. Szczylik
- Jakub Żołnierek
- Christian Kollmannsberger
- Sun Young Rha
- Georg Arnold Bjarnason
- Bohuslav Melichar
- Ugo De Giorgi
- Viktor Grünwald
- Ian D. Davis
- Jae‐Lyun Lee
- Emilio Esteban
- Gladys Urbanowitz
- Matthew S. Squires
- Mahtab Marker
- Michael M. Shi
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
- Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
- Guidelines on Renal Cell Carcinoma
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer